The landscape of hepatobiliary oncology is currently undergoing a period of profound transformation. As researchers decode the complex molecular architecture of cholangiocarcinoma and gallbladder cancer, the medical community finds itself at a pivotal junction where traditional surgical approaches are increasingly augmented by precision medicine and immunotherapy. To document this evolution, Expert Review of Gastroenterology & Hepatology—a leading publication under the Taylor & Francis umbrella—has officially issued an open call for submissions for a comprehensive new Article Collection: "Biliary Cancer Prevention and Treatment."
This initiative aims to bridge the gap between bench-side molecular discoveries and bedside clinical application, providing a centralized repository for the latest evidence-based strategies in managing these aggressive, often difficult-to-treat malignancies.
Main Facts: Addressing the Biliary Cancer Crisis
Biliary tract cancers (BTCs), including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder carcinoma, represent some of the most challenging diagnoses in modern oncology. Historically characterized by late-stage presentation and a lack of effective therapeutic options, these cancers have long been considered "orphan" diseases with poor prognosis.
The upcoming Expert Review of Gastroenterology & Hepatology collection is designed to change this narrative by focusing on four core pillars:
- Early Detection: Exploring novel biomarkers and liquid biopsy technologies that may identify disease before it reaches an unresectable stage.
- Molecular Profiling: Deep-diving into the genetic mutations (such as FGFR2 fusions or IDH1 mutations) that are currently driving the development of targeted systemic therapies.
- Surgical Innovation: Highlighting advancements in hepatobiliary surgical techniques, including minimally invasive approaches and complex liver resection strategies.
- Multidisciplinary Management: Emphasizing the necessity of "tumor boards" that integrate oncology, radiology, pathology, and surgery to optimize patient outcomes.
The journal is inviting a diverse range of submissions, including Original Research, comprehensive Reviews, Drug Profiles, and Editorial pieces that provide critical analysis of current clinical trends.
Chronology: The Path to Precision Oncology
To understand why this call for papers is so timely, one must look at the rapid evolution of hepatobiliary treatment over the past decade.
- Pre-2015: Standard of care was largely limited to gemcitabine-based chemotherapy, with very few patients eligible for curative-intent surgery.
- 2015–2019: The emergence of molecular testing began to reveal the heterogeneity of biliary cancers. Researchers started identifying "actionable" mutations, moving the field toward personalized medicine.
- 2020–2022: The FDA and other regulatory bodies began approving the first generation of targeted therapies, such as pemigatinib and ivosidenib, for patients with specific genetic profiles.
- 2023–2024: Immunotherapy (such as the addition of durvalumab to standard chemotherapy) became a new cornerstone of treatment, significantly improving survival outcomes in phase III trials.
- Present Day: The focus has shifted toward integrating these systemic advancements with enhanced surgical techniques and earlier detection methods, which is the exact scope of the new Taylor & Francis collection.
Supporting Data: Why Innovation is Critical
The global burden of biliary cancer is rising, with incidence rates steadily climbing in various regions. According to clinical data, the five-year survival rate for unresectable BTC remains stubbornly low, often hovering in the single digits. However, the data also reveals a shift in potential:
- Targeted Therapy Efficacy: Patients with specific genetic aberrations (e.g., FGFR2 fusions) who receive targeted inhibitors have shown a marked increase in progression-free survival (PFS) compared to historical chemotherapy-only cohorts.
- Immunotherapy Impact: The TOPAZ-1 trial, which solidified the role of immune checkpoint inhibitors in first-line treatment, demonstrated that combined therapy could offer long-term survival benefits for a subset of patients previously considered terminal.
- The Surgical Window: Data indicates that when patients are identified early and treated by high-volume, specialized multidisciplinary teams, the rate of R0 resections—surgeries where no cancer cells are detected at the margin—increases significantly, leading to improved long-term disease-free survival.
This collection aims to curate the latest datasets that validate these trends, providing clinicians with the granular evidence needed to advocate for molecular testing and early surgical referral.
Official Responses and Editorial Vision
The commissioning editor for this project, Olivia Clovis-Corbett, underscores the necessity of this collection as a resource for the global medical community.
"The landscape for patients with hepatobiliary malignancy is shifting faster than perhaps any other area of gastroenterology," says Clovis-Corbett. "Our goal with this Expert Review of Gastroenterology & Hepatology collection is to capture that momentum. We are not just looking for reports of success; we are looking for the clinical insights that help the practitioner navigate the complexities of these aggressive cancers. We want to hear from the surgeons, the oncologists, and the translational researchers who are defining what the future of patient care looks like."
By soliciting contributions from across the globe, Taylor & Francis hopes to foster a cross-pollination of ideas. The publisher emphasizes that high-quality translational work—research that takes findings from the lab and applies them to human patients—is of particular interest.
Implications: Changing the Future of Patient Care
The implications of this initiative extend far beyond the pages of a medical journal. By centralizing the most innovative research, this Article Collection acts as a catalyst for global clinical standard-setting.
For Clinicians
For the physician in the clinic, this collection will serve as an essential manual for navigating the "new" hepatobiliary oncology. As systemic therapies become more complex, clinicians require clear, peer-reviewed summaries of how to sequence treatments, how to interpret molecular reports, and when to refer patients for surgical consultation.
For Researchers
For those in the lab, this platform offers an opportunity to showcase findings to a highly targeted, influential audience. Highlighting emerging biomarkers or novel drug delivery systems in a respected journal like Expert Review of Gastroenterology & Hepatology can accelerate the transition of these concepts from experimental phases to clinical trials.
For Patients
Ultimately, the goal of this academic pursuit is the improvement of patient outcomes. Improved early detection strategies mean fewer patients are diagnosed at a stage where palliative care is the only option. More effective systemic therapies mean better quality of life and longer survival for those living with advanced disease. By facilitating the exchange of knowledge, Taylor & Francis is contributing to a cycle of improvement that directly benefits the patient population.
How to Contribute
The call for submissions is now open. Taylor & Francis encourages authors working in hepatobiliary surgery, medical oncology, gastroenterology, and translational science to submit their work. The journal is currently accepting:
- Original Research: Data-driven studies that introduce new techniques, drugs, or diagnostic models.
- Reviews: Comprehensive syntheses of existing literature that help clarify current treatment standards.
- Drug Profiles: Detailed analyses of emerging therapeutics currently in the pipeline.
- Editorials: Short-form commentary on the future direction of the field.
Prospective contributors are encouraged to reach out to the Commissioning Editor, Olivia Clovis-Corbett (via email at [email protected]), to discuss their potential manuscript ideas or to request further guidance on the submission process.
As the scientific community continues to push the boundaries of what is possible in biliary cancer care, this collection serves as a vital beacon of progress. It is more than just an academic exercise; it is a collaborative effort to redefine the standard of care for a disease that has been historically underserved by medical innovation. By combining the expertise of the world’s leading surgeons and oncologists, this collection will undoubtedly play a significant role in the ongoing effort to transform biliary cancer from an aggressive, life-threatening diagnosis into a manageable, and perhaps one day, curable condition.
For further details, interested parties are invited to visit the official Taylor & Francis submission portal.
About the Author
